HK1025789A1 - Recombinant vascular endothelial cell growth factor d (vegf-d) - Google Patents
Recombinant vascular endothelial cell growth factor d (vegf-d)Info
- Publication number
- HK1025789A1 HK1025789A1 HK00102970A HK00102970A HK1025789A1 HK 1025789 A1 HK1025789 A1 HK 1025789A1 HK 00102970 A HK00102970 A HK 00102970A HK 00102970 A HK00102970 A HK 00102970A HK 1025789 A1 HK1025789 A1 HK 1025789A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- vegf
- endothelial cell
- growth factor
- cell growth
- vascular endothelial
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2375196P | 1996-08-23 | 1996-08-23 | |
AUPO1825A AUPO182596A0 (en) | 1996-08-23 | 1996-08-23 | Growth factor |
AUPO3554A AUPO355496A0 (en) | 1996-11-11 | 1996-11-11 | Growth factor |
US3109796P | 1996-11-14 | 1996-11-14 | |
AUPO4954A AUPO495497A0 (en) | 1997-02-05 | 1997-02-05 | Growth factors |
US3881497P | 1997-02-10 | 1997-02-10 | |
AUPO7435A AUPO743597A0 (en) | 1997-06-19 | 1997-06-19 | Growth factor |
US5142697P | 1997-07-01 | 1997-07-01 | |
PCT/US1997/014696 WO1998007832A1 (fr) | 1996-08-23 | 1997-08-21 | Facteur d recombinant de croissance des cellules endotheliales vasculaires (vegf-d) |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1025789A1 true HK1025789A1 (en) | 2000-11-24 |
Family
ID=46149776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK00102970A HK1025789A1 (en) | 1996-08-23 | 2000-05-17 | Recombinant vascular endothelial cell growth factor d (vegf-d) |
Country Status (11)
Country | Link |
---|---|
US (14) | US6235713B1 (fr) |
EP (4) | EP0956339B1 (fr) |
JP (3) | JP2001517075A (fr) |
AT (2) | ATE434034T1 (fr) |
AU (1) | AU729880C (fr) |
CA (1) | CA2263890C (fr) |
DE (2) | DE69739469D1 (fr) |
DK (3) | DK2107109T3 (fr) |
ES (3) | ES2251740T3 (fr) |
HK (1) | HK1025789A1 (fr) |
WO (1) | WO1998007832A1 (fr) |
Families Citing this family (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6824777B1 (en) | 1992-10-09 | 2004-11-30 | Licentia Ltd. | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
US6734285B2 (en) | 1994-03-08 | 2004-05-11 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 proteins and compositions |
US7186688B1 (en) | 1994-03-08 | 2007-03-06 | Human Genome Sciences, Inc. | Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2 |
US7109308B1 (en) | 1994-03-08 | 2006-09-19 | Human Genome Sciences, Inc. | Antibodies to human vascular endothelial growth factor 2 |
US5932540A (en) | 1994-03-08 | 1999-08-03 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US6608182B1 (en) | 1994-03-08 | 2003-08-19 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 2 |
US6040157A (en) | 1994-03-08 | 2000-03-21 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
DK0751992T3 (da) | 1994-03-08 | 2006-03-06 | Human Genome Sciences Inc | Karendotelvækstfaktor 2 |
US7153827B1 (en) | 1994-03-08 | 2006-12-26 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 and methods of use |
US7423125B2 (en) | 1995-08-01 | 2008-09-09 | Vegenics Limited | Antibodies to VEGF-C |
ATE242809T1 (de) | 1995-09-08 | 2003-06-15 | Genentech Inc | Vegf-verwandtes protein |
AU7142996A (en) | 1995-09-29 | 1997-04-28 | Universita' Degli Studi Di Siena | Regulated genes and uses thereof |
US7357927B2 (en) | 1996-03-12 | 2008-04-15 | Human Genome Sciences, Inc. | Death domain containing receptors |
WO1997033904A1 (fr) | 1996-03-12 | 1997-09-18 | Human Genome Sciences, Inc. | Recepteurs contenant un domaine de mort cellulaire |
US6713061B1 (en) | 1996-03-12 | 2004-03-30 | Human Genome Sciences, Inc. | Death domain containing receptors |
US6635743B1 (en) | 1996-03-22 | 2003-10-21 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II and methods of use |
US7964190B2 (en) | 1996-03-22 | 2011-06-21 | Human Genome Sciences, Inc. | Methods and compositions for decreasing T-cell activity |
US6828426B1 (en) | 1996-07-15 | 2004-12-07 | Chugai Seiyaku Kabushiki Kaisha | VEGF-like factor |
ES2251740T3 (es) | 1996-08-23 | 2006-05-01 | Ludwig Institute For Cancer Research | Factor de crecimiento de celulas de endotelio vascular d recombinante (vegf-d). |
US7125714B2 (en) | 1997-02-05 | 2006-10-24 | Licentia Ltd. | Progenitor cell materials and methods |
US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6391311B1 (en) | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
CA2315977A1 (fr) * | 1997-12-24 | 1999-07-08 | Ludwig Institute For Cancer Research | Vecteurs d'expression et lignees cellulaires exprimant le facteur de croissance endothelial vasculaire d, et procede de traitement des melanomes |
AU765888B2 (en) * | 1997-12-24 | 2003-10-02 | Vegenics Limited | Expression vectors and cell lines expressing vascular endothelial growth factor D, and method of treating melanomas |
CA2322792C (fr) | 1998-03-17 | 2010-09-14 | Genentech, Inc. | Polypeptides homologues de vegf et bmp1 |
EP0984063A3 (fr) * | 1998-08-31 | 2000-08-16 | Eli Lilly And Company | Gene et proteine apparentee au vegf |
US20040053837A1 (en) * | 1998-09-30 | 2004-03-18 | Ludwig Institute For Cancer Research | Composition and method for modulating vasculogenesis or angiogenesis |
US20030082670A1 (en) * | 1998-09-30 | 2003-05-01 | Ulf Eriksson | Platelet-derived growth factor C, DNA coding therefor, and uses thereof |
US20030211994A1 (en) * | 1998-09-30 | 2003-11-13 | Ludwig Institute For Cancer Research | Composition and method for modulating vasculogenesis or angiogenesis |
DE69942981D1 (de) | 1998-10-09 | 2011-01-05 | Vegenics Ltd | Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie |
EP1568375A1 (fr) * | 1998-10-26 | 2005-08-31 | Ludwig Institute For Cancer Research | Utilisation des protéines VEGF-C ou VEGF-D pour la prévention de la resténose |
CN1338943A (zh) * | 1998-10-26 | 2002-03-06 | 路德维格癌症研究院 | 利用vegf-c或vegf-d基因或蛋白预防再狭窄 |
US6958147B1 (en) | 1998-10-26 | 2005-10-25 | Licentia Ltd | Use of VEGF-C to prevent restenosis |
ATE556090T1 (de) | 1998-11-10 | 2012-05-15 | Ludwig Inst Cancer Res | Verkürzter, von blutplättchen abstammender wachstumsfaktor d, dafür kodierendes dns und deren verwendung |
CA2354325C (fr) | 1998-12-07 | 2011-08-16 | Zymogenetics, Inc. | Zvegf3 homologue du facteur de croissance |
CA2355896A1 (fr) * | 1998-12-21 | 2000-06-29 | Ludwig Institute For Cancer Research | Anticorps antifacteur de croissance endotheliale vasculaire tronque et leur utilisation |
ES2291047T3 (es) * | 1998-12-22 | 2008-02-16 | Janssen Pharmaceutica N.V. | Factor de crecimiento del endotelio vascular-x. |
US6783953B1 (en) | 1998-12-22 | 2004-08-31 | Janssen Pharmaceutica N.V. | Vascular endothelial growth factor-X |
US7223724B1 (en) | 1999-02-08 | 2007-05-29 | Human Genome Sciences, Inc. | Use of vascular endothelial growth factor to treat photoreceptor cells |
CA2363779A1 (fr) | 1999-02-26 | 2000-08-31 | Human Genome Sciences, Inc. | Endokine alpha humain et methodes d'utilisation |
WO2000058511A1 (fr) | 1999-03-26 | 2000-10-05 | Ludwig Institute For Cancer Research | Dosage et therapie pour les troubles lymphatiques impliquant la tyrosine kinase flt4 (vegfr-3) |
US6764820B2 (en) | 1999-03-26 | 2004-07-20 | Ludwig Institute For Cancer Research | Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3) |
WO2000057901A1 (fr) * | 1999-03-26 | 2000-10-05 | Regeneron Pharmaceuticals, Inc. | Modulation de la permeabilite vasculaire au moyen d'activateurs de recepteurs tie2 |
US6372494B1 (en) | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
EP1206490A1 (fr) * | 1999-08-16 | 2002-05-22 | Universita Degli Studi Di Siena | Vegf-d et utilisation angiogenique de celui-ci |
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
WO2001052875A1 (fr) * | 2000-01-18 | 2001-07-26 | Ludwig Institute For Cancer Research | Inhibiteur peptidomimetique de vegf-d/vegf-c/vegf |
US6930089B2 (en) | 2000-02-04 | 2005-08-16 | D. Collen Research Foundation Vzw | Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic disease or stroke |
US7727971B2 (en) | 2000-02-04 | 2010-06-01 | Life Sciences Research Partners Vzw | Use of placental growth factor for treating ischemic muscle disease |
US7105168B1 (en) | 2002-06-04 | 2006-09-12 | D. Collen Research Foundation Vzw | Method of improving ischemic muscle function by administering placental growth factor |
WO2001057181A2 (fr) * | 2000-02-04 | 2001-08-09 | Carmeliet, Peter | UTILISATION DU FACTEUR DE CROISSANCE ENDOTHELIAL VASCULAIRE, DU FACTEUR DE CROISSANCE DU PLACENTA OU DES DEUX FACTEURS DANS LA PREVENTION OU LE TRAITEMENT DE MALADIES ISCHEMIQUES OU D'ACCIDENTS CEREBROVASCULAIRES |
SK12712002A3 (sk) | 2000-02-07 | 2003-02-04 | Abbott Gmbh & Co. Kg | Deriváty 2-benzotiazolylmočoviny a ich použitie ako inhibítorov proteínkináz |
WO2001062942A2 (fr) | 2000-02-25 | 2001-08-30 | Ludwig Institute For Cancer Research | Materiaux et procedes impliquant un hybride d"adn de facteur de croissance de l"endothelium vasculaire et de proteines |
US20020102260A1 (en) | 2000-03-02 | 2002-08-01 | Marc Achen | Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue |
AU2006201128B2 (en) * | 2000-03-02 | 2009-05-28 | Vegenics Limited | Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor D |
DK1259248T3 (da) * | 2000-03-02 | 2005-04-11 | Ludwig Inst Cancer Res | Fremgangsmåde til behandling af cancere, der udtrykker vaskulær endotelvækstfaktor D |
CA2401665A1 (fr) * | 2000-03-02 | 2001-09-07 | Ludwig Institute For Cancer Research | Procedes de traitement, d'examen et de detection de cancers exprimant le facteur d de croissance endotheliale vasculaire |
US20030171267A1 (en) | 2000-04-12 | 2003-09-11 | Rosen Craig A. | Albumin fusion proteins |
EP1278771A4 (fr) * | 2000-05-03 | 2004-06-16 | Ludwig Inst Cancer Res | Methode d'activation uniquement du recepteur-3 du facteur de croissance des cellules endotheliales vasculaires et ses utilisations |
US7273751B2 (en) | 2000-08-04 | 2007-09-25 | Human Genome Science, Inc. | Vascular endothelial growth factor-2 |
JP2004527462A (ja) * | 2000-11-01 | 2004-09-09 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | 血管新生活性のinvivo刺激 |
US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
EP1341914A2 (fr) | 2000-12-07 | 2003-09-10 | Sangamo Biosciences Inc. | Regulation de l'angiogenese au moyen de proteines a doigts de zinc |
US7611711B2 (en) * | 2001-01-17 | 2009-11-03 | Vegenics Limited | VEGFR-3 inhibitor materials and methods |
CN1494552A (zh) | 2001-01-19 | 2004-05-05 | ·��ά��֢�о�Ժ | Flt4(VEGFR-3)作为靶用于肿瘤成像和抗肿瘤治疗 |
AU2002248467A1 (en) * | 2001-02-12 | 2002-08-28 | The Penn State Research Foundation | Vegf-d expression in brain cancer |
MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
US7402312B2 (en) | 2001-04-13 | 2008-07-22 | Human Genome Sciences, Inc. | Antibodies to vascular endothelial growth factor 2 (VEGF-2) |
US7208582B2 (en) | 2001-04-13 | 2007-04-24 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
EP1406573A4 (fr) * | 2001-06-07 | 2005-03-30 | Skinmedica Inc | Milieu de culture cellulaire conditionne et utilisations de ce milieu |
CA2453161A1 (fr) * | 2001-07-12 | 2003-01-23 | Ludwig Institute For Cancer Research | Cellules endotheliales lymphatiques et procedes correspondants |
CA2457694A1 (fr) * | 2001-08-09 | 2003-02-20 | Cornell Research Foundation, Inc. | Protection du facteur de croissance derive de plaquettes du myocarde |
US20030113324A1 (en) * | 2001-10-01 | 2003-06-19 | Kari Alitalo | Neuropilin/VEGF-C/VEGFR-3 materials and methods |
US20040214766A1 (en) * | 2001-10-01 | 2004-10-28 | Kari Alitalo | VEGF-C or VEGF-D materials and methods for treatment of neuropathologies |
AU2002363369B2 (en) | 2001-10-15 | 2008-08-21 | Janssen Pharmaceutica N.V. | Substituted 4-phenyl-4-(1H-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage |
EP1997829A1 (fr) | 2001-12-21 | 2008-12-03 | Human Genome Sciences, Inc. | Protéines de fusion d'albumine |
EP1487857A4 (fr) * | 2002-03-07 | 2006-08-09 | Ludwig Inst Cancer Res | Genes de cellules endotheliales sanguines et lymphatiques |
US7241446B2 (en) * | 2002-04-01 | 2007-07-10 | Trustees Of Dartmouth College | Methods for modulating angiogenesis via VEGF |
US7510714B2 (en) * | 2002-04-01 | 2009-03-31 | Trustees Of Dartmouth College | Methods for modulating angiogenesis |
EP1551227A4 (fr) * | 2002-05-03 | 2006-05-17 | Ludwig Inst Cancer Res | Prevention de lymphoedeme secondaire avec un adn de vegf-d |
EP1531848A4 (fr) | 2002-06-10 | 2007-03-28 | Vaccinex Inc | Gene s'exprimant de fa on differentielle dans le cancer du sein et de la vessie et polypeptides codes |
AU2003252039A1 (en) | 2002-07-23 | 2004-02-09 | Vegenics Limited | Methods and compositions for activating or inhibiting vegf-d and vegf-c |
US20040120950A1 (en) * | 2002-12-20 | 2004-06-24 | Kari Alitalo | Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis |
WO2004070018A2 (fr) * | 2003-02-04 | 2004-08-19 | Ludwig Institute For Cancer Research | Modulation vegf-b et pdgf de cellules souches |
US20050032697A1 (en) * | 2003-06-12 | 2005-02-10 | Kari Alitalo | Heparin binding VEGFR-3 ligands |
US20050043235A1 (en) * | 2003-06-12 | 2005-02-24 | Kari Alitalo | Use of VEGF-C or VEGF-D in reconstructive surgery |
US20070110744A1 (en) * | 2003-09-08 | 2007-05-17 | Kari Alitalo | Lymphatic and blood endothelial cell genes |
US7284505B1 (en) | 2003-11-03 | 2007-10-23 | Paxton Stephen E | Skijor system |
US7780973B2 (en) * | 2003-12-15 | 2010-08-24 | Ethicon Endo-Surgery, Inc. | Method and device for minimally invasive implantation of biomaterial |
CA2550727A1 (fr) * | 2003-12-29 | 2005-07-14 | Centelion | Traitement de l'ischemie coronaire ou peripherique |
US20050142161A1 (en) * | 2003-12-30 | 2005-06-30 | Freeman Lynetta J. | Collagen matrix for soft tissue augmentation |
WO2005087812A1 (fr) * | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Substances d'anticorps polyvalentes et procedes pour la famille vegf/pdgf des facteurs de croissance |
WO2005087177A2 (fr) | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Anticorps chimeriques anti-vegf-d et anticorps humanises anti-vegf-d et leurs procedes d'utilisation |
EP1725678A1 (fr) * | 2004-03-12 | 2006-11-29 | Ludwig Institute For Cancer Research | Sensibilite differentielle aux medicaments |
US7595149B1 (en) | 2004-11-08 | 2009-09-29 | University Of Kentucky Research Foundation | Methods for cancer detection |
ATE553122T1 (de) | 2005-02-28 | 2012-04-15 | Sangamo Biosciences Inc | Antiangiogene methoden und zusammensetzungen |
WO2007022287A2 (fr) | 2005-08-15 | 2007-02-22 | Vegenics Limited | Vegf-a modifié aux propriétés angiogéniques améliorées |
TW200732347A (en) * | 2005-10-06 | 2007-09-01 | Trophogen Inc | VEGF analogs and methods of use |
EP1984522B1 (fr) | 2006-01-18 | 2010-08-11 | The General Hospital Corporation | Methodes d'augmentation de la fonction lymphatique |
WO2007136679A2 (fr) | 2006-05-17 | 2007-11-29 | Ludwig Institute For Cancer Research | Cibler la régulation du vegf-b des transporteurs d'acides gras afin de moduler les maladies humaines |
EP2125895B1 (fr) | 2007-02-02 | 2015-04-08 | Vegenics Pty Ltd | Antagoniste du recepteur de facteurs de croissance pour l'allo-immunite de greffe d'organe et l'arteriosclerose |
WO2008096268A2 (fr) * | 2007-02-07 | 2008-08-14 | Vegenics Limited | Transfert de noeud de lymphe autologue en combinaison avec une thérapie de facteur croissant vegf-c ou vegf-d pour traiter un second lymphoedème et pour améliorer la chirurgie réparatrice |
US7811776B2 (en) | 2007-12-05 | 2010-10-12 | University Of Cincinnati | Use of VEGF-D in the diagnosis of lymphangioleiomyomatosis (LAM) disease |
WO2009082485A1 (fr) | 2007-12-26 | 2009-07-02 | Vaccinex, Inc. | Thérapies de combinaison par anticorps anti-c35 et procédés |
US20110142839A1 (en) * | 2008-05-30 | 2011-06-16 | Vegenics Limited | Treatment of pulmonary edema |
US20100029491A1 (en) * | 2008-07-11 | 2010-02-04 | Maike Schmidt | Methods and compositions for diagnostic use for tumor treatment |
US8255807B2 (en) * | 2008-12-23 | 2012-08-28 | Ganz | Item customization and website customization |
EP2427496A4 (fr) * | 2009-04-03 | 2013-05-15 | Vegenics Pty Ltd | Anticorps anti-vegf-d |
WO2011056494A1 (fr) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Combinaisons d'antagonistes de la kinase-1 du type récepteur de l'activine et d'antagonistes vegfr3 |
US9011861B2 (en) * | 2010-02-25 | 2015-04-21 | Schepens Eye Research Institute | Therapeutic compositions for the treatment of dry eye disease |
WO2011154308A1 (fr) | 2010-06-08 | 2011-12-15 | Proyecto De Biomedicina Cima, S.L. | Nouvelles compositions et procédés de thérapie cellulaire dans le traitement de la cirrhose |
WO2012088563A1 (fr) * | 2010-11-24 | 2012-07-05 | Vegenics Pty Limited | Formes spécifiques du vegfr-2 de vegf-d et vegf-c et utilisations associées |
US8852592B2 (en) | 2011-05-10 | 2014-10-07 | Biocare Medical, Llc | Systems and methods for anti-PAX8 antibodies |
US9415090B2 (en) * | 2011-06-01 | 2016-08-16 | Universität Heidelberg | VEGF-D/VEGFR2/3-mediated regulation of dendrites |
US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
US10457713B2 (en) | 2012-07-30 | 2019-10-29 | Trophogen, Inc. | Glycoprotein hormone long-acting superagonists |
RS58881B1 (sr) | 2012-07-30 | 2019-08-30 | Trophogen Inc | Dugodelujući superagonisti glikoproteinskih hormona |
EP2900265B1 (fr) | 2012-09-27 | 2018-05-30 | Biocare Medical, LLC | Anticorps anti-uroplakine ii et méthodes associées |
US10429390B2 (en) | 2012-12-18 | 2019-10-01 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
CA2901226C (fr) | 2013-02-18 | 2020-11-17 | Vegenics Pty Limited | Proteines liant le facteur de croissance de l'endothelium vasculaire |
EP2962113B1 (fr) | 2013-02-28 | 2019-04-03 | Biocare Medical, LLC | Anticorps anti-p40, systèmes et procédés |
ES2765423T3 (es) | 2013-10-03 | 2020-06-09 | Biocare Medical Llc | Sistemas y procedimientos de anticuerpos anti-SOX10 |
KR20160101906A (ko) | 2013-11-05 | 2016-08-26 | 트로포젠 인코포레이티드 | 당단백질 호르몬의 장시간-작용하는 초작용제 |
EP3924367A4 (fr) * | 2019-04-04 | 2022-10-12 | Sree Chitra Tirunal Institute for Medical Sciences and Technology | Facteur de croissance endothélial vasculaire (vegf) pour une meilleure cicatrisation de plaie par angiogenèse améliorée |
CN116981778A (zh) * | 2021-03-10 | 2023-10-31 | 住友制药株式会社 | 半胱氨酸结蛋白的制造方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5968778A (en) | 1989-01-12 | 1999-10-19 | Jurgen Hoppe | PDGF-AB, preparation process and pharmaceuticals containing them |
US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US6207454B1 (en) * | 1989-10-16 | 2001-03-27 | Amgen Inc. | Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide |
US5476839A (en) * | 1990-07-10 | 1995-12-19 | Incyte Pharmaceuticals, Inc. | Basophil granule proteins |
JP3024311B2 (ja) | 1991-10-03 | 2000-03-21 | 味の素株式会社 | Il−2受容体重鎖に結合するポリペプチド |
JPH05271294A (ja) | 1992-01-24 | 1993-10-19 | Japan Found Cancer Res | ヒトプロヒビチンおよびそれをコードするdna |
RU2104286C1 (ru) | 1992-07-27 | 1998-02-10 | Пфайзер Инк. | Полипептид или его фармацевтически приемлемые соли |
US5510239A (en) * | 1993-10-18 | 1996-04-23 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of multidrug resistance-associated protein |
DK0751992T3 (da) * | 1994-03-08 | 2006-03-06 | Human Genome Sciences Inc | Karendotelvækstfaktor 2 |
DE4423098A1 (de) | 1994-07-01 | 1996-01-04 | Hoechst Ag | Verwendung von Pyrimidingruppen enthaltenden konjugierten Verbindungen als Elektrolumineszenzmaterialien |
US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
US6221839B1 (en) * | 1994-11-14 | 2001-04-24 | Helsinki University Licensing Ltd. Oy | FIt4 ligand and methods of use |
US6645933B1 (en) * | 1995-08-01 | 2003-11-11 | Helsinki University Licensing Ltd. Oy | Receptor ligand VEGF-C |
JPH08185216A (ja) | 1994-12-28 | 1996-07-16 | Meidensha Corp | 工具姿勢パラメータ設定方法及びロボット制御装置 |
US5928939A (en) | 1995-03-01 | 1999-07-27 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-b and dna coding therefor |
KR100414615B1 (ko) | 1995-03-02 | 2004-05-27 | 암레드 오퍼레이션즈 피티와이, 리미티드 | 신규의증식인자및이를암호하는유전자서열 |
CA2224002A1 (fr) | 1995-06-06 | 1996-12-12 | Human Genome Sciences, Inc. | Facteur de croissance 3 de l'endothelium vasculaire humain |
ATE242809T1 (de) * | 1995-09-08 | 2003-06-15 | Genentech Inc | Vegf-verwandtes protein |
AU7142996A (en) | 1995-09-29 | 1997-04-28 | Universita' Degli Studi Di Siena | Regulated genes and uses thereof |
JP3843488B2 (ja) | 1996-06-06 | 2006-11-08 | アイシン・エィ・ダブリュ株式会社 | 自動変速機の制御装置 |
US6828426B1 (en) * | 1996-07-15 | 2004-12-07 | Chugai Seiyaku Kabushiki Kaisha | VEGF-like factor |
ES2251740T3 (es) | 1996-08-23 | 2006-05-01 | Ludwig Institute For Cancer Research | Factor de crecimiento de celulas de endotelio vascular d recombinante (vegf-d). |
WO1998024811A2 (fr) * | 1996-12-06 | 1998-06-11 | Zymogenetics, Inc. | Facteur de croissance endotheliale vasculaire |
US20020165174A1 (en) * | 1997-01-31 | 2002-11-07 | Gill Parkash S. | Methods and compositions for antisense VEGF oligonucleotides |
CA2315977A1 (fr) | 1997-12-24 | 1999-07-08 | Ludwig Institute For Cancer Research | Vecteurs d'expression et lignees cellulaires exprimant le facteur de croissance endothelial vasculaire d, et procede de traitement des melanomes |
DE19817835C2 (de) | 1998-04-22 | 2000-05-18 | Billhofer Maschf Gmbh | Sichtkaschiervorrichtung |
DE19823359C1 (de) | 1998-05-15 | 1999-10-07 | Francotyp Postalia Gmbh | Vorrichtung zum Bedrucken von Postgut |
CA2355896A1 (fr) | 1998-12-21 | 2000-06-29 | Ludwig Institute For Cancer Research | Anticorps antifacteur de croissance endotheliale vasculaire tronque et leur utilisation |
EP1206490A1 (fr) * | 1999-08-16 | 2002-05-22 | Universita Degli Studi Di Siena | Vegf-d et utilisation angiogenique de celui-ci |
US20050043235A1 (en) | 2003-06-12 | 2005-02-24 | Kari Alitalo | Use of VEGF-C or VEGF-D in reconstructive surgery |
US20070212390A1 (en) | 2005-09-22 | 2007-09-13 | Ludwig Institute For Cancer Research | Protease-resistant forms of VEGF-D, method of making and method of use |
FR2987282B1 (fr) | 2012-02-24 | 2017-12-29 | Fonds De L'espci Georges Charpak | Microcanal avec dispositif d'ouverture et/ou fermeture et/ou pompage |
US9405291B2 (en) | 2012-07-31 | 2016-08-02 | Fisher-Rosemount Systems, Inc. | Systems and methods to monitor an asset in an operating process unit |
US9516755B2 (en) | 2012-12-28 | 2016-12-06 | Intel Corporation | Multi-channel memory module |
US9426605B2 (en) | 2013-10-10 | 2016-08-23 | Yahoo! Inc. | Cross device information exchange using gestures and locations |
-
1997
- 1997-08-21 ES ES97938486T patent/ES2251740T3/es not_active Expired - Lifetime
- 1997-08-21 WO PCT/US1997/014696 patent/WO1998007832A1/fr active IP Right Grant
- 1997-08-21 JP JP51095398A patent/JP2001517075A/ja active Pending
- 1997-08-21 ES ES09162873T patent/ES2390107T3/es not_active Expired - Lifetime
- 1997-08-21 CA CA2263890A patent/CA2263890C/fr not_active Expired - Fee Related
- 1997-08-21 DK DK09162873.5T patent/DK2107109T3/da active
- 1997-08-21 EP EP97938486A patent/EP0956339B1/fr not_active Revoked
- 1997-08-21 DE DE69739469T patent/DE69739469D1/de not_active Expired - Lifetime
- 1997-08-21 DK DK06121918T patent/DK1749836T3/da active
- 1997-08-21 AU AU40796/97A patent/AU729880C/en not_active Ceased
- 1997-08-21 EP EP09162873A patent/EP2107109B1/fr not_active Expired - Lifetime
- 1997-08-21 DK DK97938486T patent/DK0956339T3/da active
- 1997-08-21 EP EP06121918A patent/EP1749836B1/fr not_active Expired - Lifetime
- 1997-08-21 EP EP02018842A patent/EP1283268A3/fr not_active Withdrawn
- 1997-08-21 ES ES06121918T patent/ES2327440T3/es not_active Expired - Lifetime
- 1997-08-21 DE DE69734359T patent/DE69734359T2/de not_active Expired - Lifetime
- 1997-08-21 US US08/915,795 patent/US6235713B1/en not_active Expired - Fee Related
- 1997-08-21 AT AT06121918T patent/ATE434034T1/de not_active IP Right Cessation
- 1997-08-21 AT AT97938486T patent/ATE306546T1/de not_active IP Right Cessation
-
1999
- 1999-04-22 US US09/296,275 patent/US6689580B1/en not_active Expired - Fee Related
-
2000
- 2000-05-17 HK HK00102970A patent/HK1025789A1/xx not_active IP Right Cessation
-
2002
- 2002-06-05 US US10/161,694 patent/US7410639B2/en not_active Expired - Fee Related
- 2002-10-22 US US10/274,953 patent/US7122654B2/en not_active Expired - Fee Related
-
2003
- 2003-11-12 US US10/705,476 patent/US20040175730A1/en not_active Abandoned
-
2005
- 2005-12-16 US US11/304,585 patent/US20060177428A1/en not_active Abandoned
-
2007
- 2007-01-24 JP JP2007013569A patent/JP2007167072A/ja active Pending
- 2007-03-28 US US11/692,753 patent/US20080145366A1/en not_active Abandoned
- 2007-06-29 US US11/772,089 patent/US7662932B2/en not_active Expired - Fee Related
- 2007-08-23 US US11/843,867 patent/US7871798B2/en not_active Expired - Fee Related
- 2007-10-30 US US11/929,537 patent/US7785803B2/en not_active Expired - Fee Related
- 2007-10-30 US US11/929,120 patent/US7928061B2/en not_active Expired - Fee Related
-
2009
- 2009-07-10 JP JP2009164162A patent/JP2009291198A/ja active Pending
-
2011
- 2011-03-16 US US13/049,308 patent/US8227410B2/en not_active Expired - Fee Related
-
2012
- 2012-05-17 US US13/474,273 patent/US8445234B2/en not_active Expired - Fee Related
-
2013
- 2013-04-19 US US13/866,266 patent/US8759286B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1025789A1 (en) | Recombinant vascular endothelial cell growth factor d (vegf-d) | |
EP0814827A4 (fr) | Facteur de croissance-b des cellules endotheliales vasculaires | |
EP1129110A4 (fr) | Facteur de croissance d d'origine plaquettaire, l'adn codant pour celui-ci, et ses utilisations | |
DE3851153D1 (de) | Genetische modifizierung von endothelialen zellen. | |
AU568067B2 (en) | Oligonucleotide therapeutic agent and methods of making same | |
EP0897987A3 (fr) | Sécretion de protéine humaine associée au peptide-signal de l' interferon gamma | |
CA2095153A1 (fr) | Modification genetique de cellules endotheliales | |
EP1308515A3 (fr) | Facteur VIII porcin | |
ZA943464B (en) | Vascular endothelial growth factor 2 | |
WO1993016099A3 (fr) | Sequences d'adn codant de nouveaux facteurs de croissance/differentiation | |
DE69018920D1 (de) | Verwendung von dns-fragmenten, die ein signalpeptid kodieren zur sekretion von reifen proteinen in rekombinanten hefen, expressions-kassetten, transformierte hefen und verfahren zur herstellung dieser proteine. | |
WO1998049300A3 (fr) | Formes tronquees de proteines apparentees au facteur vegf | |
IL70776A (en) | Recombinant dna molecule encoding at least one polypeptide displaying the immunogenicity of at least one merozoite antigen or asexual blood stage antigen of p.falciparum,vectors comprising the dna molecule,host cells transformed thereby,immunogenic polypeptides produced by host cells and compositions containing the polypeptides | |
EP0349342A3 (fr) | Polypeptides ayant une activité dispersante de cellules | |
AU7869487A (en) | Expression of biologically active factor XIII | |
MXPA00002318A (es) | Celulas geneticamente disenadas que expresan proteinas morfogeneticas de hueso. | |
WO2001053324A8 (fr) | Nouveaux peptides haptotactiques | |
WO2001040257A3 (fr) | Polypeptides cytokines et acides nucleiques | |
WO1990003394A3 (fr) | Nouvelles lymphokines, sequences d'adn codant pour ces lymphokines et compositions pharmaceutiques contenant ces lymphokines | |
EP0316115A3 (fr) | Vecteurs et séquences d'expression pour la préparation de polypeptides | |
Cimdins et al. | Comparative study of tissue reactions of calcium phosphate and alumina ceramics | |
WO2002059618A3 (fr) | Polypeptides de facteur de croissance et acides nucleiques codant pour ces polypeptides | |
MY103637A (en) | Neutrophil-activating factor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20090821 |